Clinical Trials Browser

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Carcinoma, Merkel Cell

NCT03477864 2025-04-29

Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer

Phase 1 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT03951831 2025-04-25

REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

Phase 2 Active not recruiting

26 enrolled

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT04382898 2025-03-20

PRO-MERIT

Phase 1/2 Terminated

75 enrolled 17 charts

Genitourinary

Prostatic Neoplasms

NCT03367819 2022-05-16

Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies

Phase 1/2 Terminated

44 enrolled 24 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms

Clinical Trials

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer

REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

PRO-MERIT

Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies